<DOC>
	<DOCNO>NCT00131066</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety profile psoriasis patient complete participation previous study receive treatment MEDI-507 .</brief_summary>
	<brief_title>Long-Term Follow-Up Study Psoriasis Patients</brief_title>
	<detailed_description>This study evaluate long-term safety lymphocyte repletion profile psoriasis patient complete participation previous study receive treatment MEDI-507 . Patients must ALC &gt; 30 % low baseline ( defined baseline prior MEDI-507 exposure ) ; absolute CD4 count &lt; 250 cells/uL . This study also evaluate development durability anti-MEDI-507 antibody .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>The patient previously complete participation ( i.e. , complete per protocol , include long term followup ; discontinue study due withdrawal consent , loss followup , reason ) Medimmune , Inc. study MEDI507 psoriasis receive MEDI507 ( placebo patient participate blind placebocontrolled study MEDI507 , treatment assignment study unblinded time entry study ) The patient absolute lymphocyte count ( ALC ) &gt; 30 % low baseline ( defined baseline prior MEDI507 exposure ; , patient whose treatment assignment unblinded time entry study , drug exposure ) his/her final visit ( exclude longterm followup visit ) recent Medimmune , Inc. study patient participate ; patient absolute CD4 count &lt; 250 cells/uL his/her final visit ( include protocolspecific longterm follow ) recent Medimmune , Inc. study patient participate . Written inform consent obtain patient There exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Previously enrol MEDI-507 psoriasis</keyword>
</DOC>